Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.
Front Oncol. 2019;9:415
Sci Rep. 2019 May 14;9(1):7390
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Cancer Cell. 2019 May 13;35(5):738-751.e9
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
J Immunother Cancer. 2019 Mar 13;7(1):72
Oncologist. 2019 Mar 04;:
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Cancer. 2019 Feb 15;:
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.
Target Oncol. 2019 Feb 11;:
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Oncologist. 2019 Feb 06;:
Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck.
Clin Transl Radiat Oncol. 2019 Feb;15:13-19
Cancer Med. 2018 Dec 21;: